Pure Global
NCT06302699

Detecting Minimal Residual Diseases (MRD) and Monitoring Clonal Evolution Using Ultrasensitive Chromosomal Aberrations Detection (UCAD) in Multiple Myeloma

Clinical Utility of Ultrasensitive Chromosomal Aberrations Detection (UCAD) for Detecting Minimal Residual Disease (MRD) and Monitoring Clonal Evolution by Low-Pass Whole Genome Sequencing in Multiple Myeloma
Institute of Hematology & Blood Diseases Hospital, China·ClinicalTrials.govRecruiting
View on ClinicalTrials.gov →
Study focus
Disease/Condition
Multiple Myeloma
Study type
Observational
Sponsor & location
Primary sponsor
Institute of Hematology & Blood Diseases Hospital, China
Timeline & enrollment
Phase
N/A
Start date
May 01, 2023
End date
Mar 01, 2026
Enrollment
80 participants
Primary outcome

Detection of copy number variation

Summary

The presence of minimal residual disease (MRD) is an important prognostic factor for multiple
 myeloma, while copy number variation (CNV) is a widely accepted biomarker used for multiple
 myeloma (MM). Detecting MRD and monitoring clonal evolution by monitoring CNV using low-pass
 whole genome sequencing is promising due to its high analytical sensitivity. To evaluate the
 correlation between MRD detected by flow cytometry and low-pass whole genome sequencing,
 nearly 200 samples were collected for this study. We applied ultrasensitive chromosomal
 aberrations detection to detect CNV for each patient. The follow-up samples were then
 collected and sequencing used the same method.

ICD-10 classifications
Multiple myelomaMultiple myeloma and malignant plasma cell neoplasmsOther myeloid leukaemiaMyeloid leukaemiaOther myelodysplastic syndromes
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06302699
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06302699 through Pure Global AI's free database. This phase not specified trial is sponsored by Institute of Hematology & Blood Diseases Hospital, China and is currently Recruiting. The study focuses on Multiple Myeloma. Target enrollment is 80 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.